2018
Trends in Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
Gani F, Conca-Cheng AM, Nettles B, Ahuja N, Johnston FM. Trends in Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Journal Of Surgical Research 2018, 234: 240-248. PMID: 30527480, DOI: 10.1016/j.jss.2018.09.032.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinomaChemotherapy, Cancer, Regional PerfusionCombined Modality TherapyCytoreduction Surgical ProceduresDatabases, FactualFemaleHumansHyperthermia, InducedLogistic ModelsMaleMiddle AgedPatient SelectionPeritoneal NeoplasmsPostoperative ComplicationsRisk FactorsTreatment OutcomeConceptsCRS/HIPECHyperthermic intraperitoneal chemotherapyMedian operative timeLength of stayPostoperative morbidityCytoreductive surgeryOperative timeIntraperitoneal chemotherapySelect patientsClinical outcomesSurgeons National Surgical Quality Improvement Program databaseNational Surgical Quality Improvement Program databaseCommon primary tumor siteQuality Improvement Program databaseMultivariable logistic regression analysisLow preoperative hematocritImprovement Program databasePreoperative serum albuminCareful patient selectionPrimary tumor siteLogistic regression analysisPostoperative complicationsPostoperative deathsPreoperative hematocritPeritoneal carcinomatosis
2009
Methylation of TFPI2 in Stool DNA: A Potential Novel Biomarker for the Detection of Colorectal Cancer
Glöckner S, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, Chan TA, Kleeberger W, de Bruïne A, Smits KM, Bakker C, Jonkers DM, Stockbrügger R, Meijer GA, Oort FA, Iacobuzio-Donahue C, Bierau K, Herman JG, Baylin SB, Van Engeland M, Schuebel KE, Ahuja N. Methylation of TFPI2 in Stool DNA: A Potential Novel Biomarker for the Detection of Colorectal Cancer. Cancer Research 2009, 69: 4691-4699. PMID: 19435926, PMCID: PMC3062162, DOI: 10.1158/0008-5472.can-08-0142.Peer-Reviewed Original ResearchConceptsTissue factor pathway inhibitor-2Colorectal cancerStool DNATFPI2 methylationStage INonmetastatic colorectal cancerHuman colorectal cancerPotential novel biomarkersCRC patientsNoncancer controlsColorectal carcinogenesisNovel biomarkersUseful adjunctPotential tumor suppressor geneNoninvasive strategyTumor suppressor geneEarly detectionAberrant DNA methylationPatientsFrequent eventCancerAberrant methylationSuppressor geneBiomarkers
2008
Abnormal DNA Methylation of CD133 in Colorectal and Glioblastoma Tumors
Yi JM, Tsai HC, Glöckner S, Lin S, Ohm JE, Easwaran H, James CD, Costello JF, Riggins G, Eberhart CG, Laterra J, Vescovi AL, Ahuja N, Herman JG, Schuebel KE, Baylin SB. Abnormal DNA Methylation of CD133 in Colorectal and Glioblastoma Tumors. Cancer Research 2008, 68: 8094-8103. PMID: 18829568, PMCID: PMC2744404, DOI: 10.1158/0008-5472.can-07-6208.Peer-Reviewed Original ResearchMeSH KeywordsAC133 AntigenAnimalsAntigens, CDAntineoplastic AgentsAzacitidineBrain NeoplasmsCaco-2 CellsCarcinomaColorectal NeoplasmsDecitabineDNA (Cytosine-5-)-MethyltransferasesDNA MethylationFemaleGene DeletionGene Expression Regulation, NeoplasticGlioblastomaGlycoproteinsHCT116 CellsHT29 CellsHumansMiceMice, NudePeptidesTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsDNA methylationMethylation patternsPromoter DNA methylation patternsHistone modification marksDNA methylation patternsDNA methylation changesDNA methylation statusPromoter CpG islandsAberrant DNA methylationAbnormal DNA methylationCultured colon cancerStem-like cell populationTranscription stateModification marksPromoter signaturesCpG islandsSuch methylationIndividual cell linesMethylation changesAberrant genesDifferentiated progenyMethylationMarker proteinsMethylation statusGenes
1998
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
Herman J, Umar A, Polyak K, Graff J, Ahuja N, Issa J, Markowitz S, Willson J, Hamilton S, Kinzler K, Kane M, Kolodner R, Vogelstein B, Kunkel T, Baylin S. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 6870-6875. PMID: 9618505, PMCID: PMC22665, DOI: 10.1073/pnas.95.12.6870.Peer-Reviewed Original ResearchConceptsCpG islandsMismatch repair genesCell linesDNA mismatch repairMMR-deficient cell linesDNA methylationSuch methylationSporadic primary colorectal cancerEpigenetic inactivationMMR capacityMismatch repairRepair genesMethylationFunctional consequencesColorectal cancer cell linesCancer cell linesPromoter hypermethylationHypermethylationMicrosatellite instabilityProtein expressionHMLH1 proteinGenesColorectal cancerHMLH1 protein expressionInactivation